Abstract
Women transitioning into menopause, particularly those who experience hot flashes, face the challenging decision about whether or not to initiate hormone therapy (HT). Those who choose to take HT must also decide how long to continue treatment. The Women's Health Initiative Memory Study (WHIMS), the only randomized controlled trial of the effects of HT on incident dementia, found that conjugated equine estrogen (CEE), when combined with medroxyprogesterone acetate, doubled the risk of dementia in women who initiated treatment at age 65 years and later.1 Unopposed CEE (i.e., without medroxyprogesterone acetate) did not increase the incidence of dementia, but a pooled analysis of both treatment arms revealed a 76% increased incidence of dementia.2
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
